Latest news with #MarianneDeBacker
Business Wire
2 days ago
- Business
- Business Wire
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10 at 1:00 p.m. PT / 4:00 p.m. ET in Miami Beach, Florida. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Business Wire
20-05-2025
- Business
- Business Wire
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, Ph.D., MBA, Chief Executive Officer, and Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head, Oncology, will participate in a virtual fireside chat at the TD Cowen 6 th Annual Oncology Innovation Summit on Tuesday, May 27 at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Business Wire
12-05-2025
- Business
- Business Wire
Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14 at 1:40 p.m. PT / 4:40 p.m. ET in Las Vegas, Nevada. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Yahoo
14-03-2025
- Health
- Yahoo
Vir enrols first subject in Phase III programme to assess CHD therapy
Vir Biotechnology has enrolled the first subject in the Phase III ECLIPSE registrational programme of tobevibart and elebsiran in individuals with chronic hepatitis delta (CHD), an inflammatory liver condition. The programme is designed to assess the safety and efficacy of the combination in this patient population. It includes the ECLIPSE 1 and ECLIPSE 2 Phase III trials, aiming to offer the registrational data required for regulatory submissions. The Phase IIb ECLIPSE 3 trial seeks to support access and reimbursement strategies in the European markets. ECLIPSE 1 aims to enrol 120 subjects across the US and other select regions, comparing the combination therapy to deferred treatment. Subjects will be randomised to receive either the combination or deferred treatment. Measuring HDV RNA and serum alanine aminotransferase normalisation at week 48 will be the trial's primary endpoint. ECLIPSE 2 focuses on subjects who have not obtained viral suppression with bulevirtide treatment, while ECLIPSE 3, the head-to-head trial, will evaluate the combination with bulevirtide in treatment-naïve individuals. CHD is said to occur due to the hepatitis delta virus (HDV), leading to cirrhosis and liver failure within five years for many people affected. Vir Biotechnology CEO Marianne De Backer said: 'The start of the ECLIPSE programme marks a pivotal moment for patients living with hepatitis delta and for Vir Biotechnology. 'With a proven track record of developing treatments powering the immune system to transform lives, this achievement is a testament to our ability to rapidly advance impactful treatments from discovery to patient care.' Tobevibart, a monoclonal antibody, and elebsiran, a small interfering ribonucleic acid, are the investigational candidates that were discovered by Vir Biotechnology and Alnylam Pharmaceuticals, respectively. The combination therapy received breakthrough and fast track designation from the US Food and Drug Administration, as well as orphan drug and priority medicines status from the European Medicines Agency. In September 2023, Vir dosed the first subject in the Phase I HVTN 142 trial of VIR-1388, a T-cell vaccine candidate aimed at preventing human immunodeficiency virus. "Vir enrols first subject in Phase III programme to assess CHD therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
